NCT07668466尚未招募1 期
A Phase I/II, Open-label, Single Administration Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration
Cartago Biotech Pty Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年7月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
The goal of this clinical trial is to find out if a new medicine can help people who have long-lasting back pain caused by damaged spinal discs. The study will also check if the medicine is safe to use.
The main questions this study aims to answer are:
Is the medicine safe, and what amount works best? Can it reduce long-term back pain?
Researchers will test a medicine called CBT005, which contains a healing protein, by injecting it into the spinal discs. They will watch closely to see how people respond to the treatment.
Participants will:
Receive one study injection into the spinal disc Visit the clinic in person during the first 12 months for checkups Receive phone calls at 24 and 36 months to see how they are doing Still be able to get other pain treatments in the future, including surgery, if needed
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
In Phase 2, outcome assessor and participant will be masked
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Persistent low back pain, with at least 3 months of non-surgical therapy, at one symptomatic disc or two symptomatic lumbar disc levels (from L2 to S1).
- •MRI scans show Pfirrmann disc degeneration grade 2 to 4 or High Intensity Zone (HIZ) signal change with or without Modic endplate changes.
- •Symptoms are a fair bit or a lot bothersome, which require medication or other types of treatments or very disrupting (in response to question*).
- •Preoperative Oswestry Disability Index (ODI) score greater than or equal to 30%
- •Visual Analog Score for back pain ≥40 mm.
- •Any gender, 18 years of age or older
- •Clinician diagnosed discogenic pain
- •A signed HREC-approved Informed Consent Form
- •Able to meet the protocol follow-up schedule and activities
- •Females of childbearing potential must have a negative urine/serum pregnancy test at screening (Baseline Visit) and on the day of administration prior to injection *Question defined in full protocol
排除标准
- •People unable to have an MRI
- •Abnormal neurological exam at baseline (e.g., chronic radiculopathy)
- •Active radicular pain due to anatomical compression such as stenosis or disc herniation
- •Symptomatic facet joints and/or severe facet degeneration at the index level or adjacent segments
- •Symptomatic Sacro-iliac joint
- •MRI findings demonstrate any of the following: Suspected disc appears normal or >50% decrease in disc height or Presence of symptomatic osteophytes
- •Any prior lumbar spinal surgeries at suspected symptomatic level; prior surgery at the adjacent levels is acceptable including fusion or arthroplasty, provided the said adjacent level is not independently symptomatic.
- •Presence of spondylolisthesis (anterolisthesis, retrolisthesis is acceptable)
- •Symptomatic disc degeneration at more than 2 lumbar levels (multi-level disc degeneration based on MRI findings is acceptable with up to two symptomatic level. Only the symptomatic levels will be treated)
- •Evidence of active infection
- •Immunosuppressive therapy within 3 months prior to investigational product administration
- •Either continuous or cumulative use of more than 2 months use in the past 6 months of an oral or systemic steroid. Inhaled steroids are acceptable
- •Tumor in the spine
- •People with any current and previous cancer. An exemption to this is previous BCCs which have been successfully removed.
- •Non-contained herniated nucleus pulposus
- •Any prior intradiscal therapies (chemonucleolysis, IDET, intradiscal steroid injection) at the same level being treated, other than rhGDF-
- •Any non-intradiscal steroid injection less than 2 months prior to administration. Does not include isolated joint injections outside the lumbar region.
- •Nerve block injection less than 2 months prior to injection of study medication.
- •Known autoimmune disease
- •Type 1 Insulin-dependent diabetes mellitus (Type II, non-insulin dependent diabetes mellitus is allowed)
- •Pregnant or lactating, or wishes to become pregnant within the first 12 months of the study
- •Involved in pending litigation of the spine (including workers compensation cases)
- •Demonstrates signs of non-organic pain (e.g., Waddell's Signs)
- •Based on clinical history, physical examination and participant presentation, participant has, or is suspected to have, a history of alcohol and/or drug abuse that would preclude participants from providing adequate consent and/or complying with study requirements
- •Morbid Obesity, defined as Body Mass Index (BMI) ≥40
- •Life expectancy less than 2 years
- •Any significant psychological disturbance past or present, that could impair the consent process or ability to complete participant self-report questionnaires
- •Any reason not cited above that, in the opinion of the Principal Investigator, would pose a risk to either the participant or to the integrity of the clinical trial
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVIDNCT07627815ParagonClinicals Inc.82
尚未招募
1 期
Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)AspartylglucosaminuriaAspartylglucosamidase (AGA) DeficiencyNCT07530796Rare Trait Hope9
尚未招募
3 期
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT07569757Chia Tai Tianqing Pharmaceutical Group Co., Ltd.260
招募中
3 期
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb SpasticityNCT07478822Chongqing Claruvis Pharmaceutical Co., Ltd.300
尚未招募
3 期
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.NCT07608159Shanghai Pulmonary Hospital, Shanghai, China201